Shylendra B. Sreenivasappa
Expertise in
38
conditions

Dr. Shylendra B. Sreenivasappa

Hematology | Oncology | Internal Medicine
5666 East State Street, 
Rockford, IL 
Offers Telehealth
Expertise in
38
conditions
5666 East State Street, 
Rockford, IL 

Overview

Shylendra Sreenivasappa is a Hematologist and an Internal Medicine provider practicing medicine in Rockford, Illinois.

Dr. Sreenivasappa is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Iron Deficiency Anemia, Lynch Syndrome, Familial Colorectal Cancer, and Bone Marrow Aspiration.

Dr. Sreenivasappa is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, participating in 14 clinical trials.

Graduate Institution

Kempegowda Institute Of Medical Sciences, 2002

Residency

John H. Stroger, Jr. Hospital of Cook County, Internal Medicine, 2007

Specialties

Hematology
Oncology
Internal Medicine

Licenses

Internal Medicine in IL

Board Certifications

American Board Of Internal Medicine

Fellowships

John H. Stroger, Jr. Hospital of Cook County, Hematology and Oncology, 2010

Hospital Affiliations

Osf Saint Elizabeth Mdl Ctr
Saint Anthony Medical Center
Osf Saint Paul Medical Center
Rochelle Community Hospital
Javon Bea Hospital

Languages Spoken

English
Kannada

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Pekin Life
  • MEDICARE PDP
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 11 Less Insurance Carriers -

Locations

OSF Saint Anthony - Cancer Center
5666 East State Street, Rockford, IL 61108

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Other, Drug
Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Behavioral
Study Phase: Phase 3
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
View 9 Less Clinical Trials
Similar Doctors
Expertise in
73
conditions
Dr. Rajini Manjunath
Hematology | Oncology
Expertise in
73
conditions
Dr. Rajini Manjunath
Hematology | Oncology
Referral may be required

Illinois Cancer Specialists

1710 N Randall Rd, 
Elgin, IL 
 (36.9 miles away)
847-931-0909
Languages Spoken:
English, Hindi, Kannada
See accepted insurances
Offers Telehealth

Rajini Manjunath is a Hematologist and an Oncologist practicing medicine in Elgin, Illinois. Dr. Manjunath is highly rated in 73 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Hemangioma Thrombocytopenia Syndrome, Immune Thrombocytopenic Purpura (ITP), and Bone Marrow Aspiration. Dr. Manjunath is board certified in American Board Of Internal Medicine, Hematology.

Expertise in
29
conditions
Dr. Avanthi Ragam
Hematology | Oncology
Expertise in
29
conditions
Dr. Avanthi Ragam
Hematology | Oncology
Referral may be required
304 Randall Rd, 
Geneva, IL 
 (43.2 miles away)
630-208-4060
Experience:
26+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Avanthi Ragam is a Hematologist and an Oncologist practicing medicine in Geneva, Illinois. She has been practicing medicine for over 26 years. Dr. Ragam is highly rated in 29 conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, and Non-Small Cell Lung Cancer (NSCLC). Dr. Ragam is board certified in American Board Of Internal Medicine - Hematology (Certified).

Expertise in
103
conditions
Dr. Veerpal Singh
Hematology | Oncology
Expertise in
103
conditions
Dr. Veerpal Singh
Hematology | Oncology
Referral may be required

Illinois Cancer Specialists

1710 N Randall Rd, 
Elgin, IL 
 (36.9 miles away)
847-931-0909
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Veerpal Singh is a Hematologist and an Oncologist practicing medicine in Elgin, Illinois. Dr. Singh is highly rated in 103 conditions, according to our data. His clinical expertise encompasses Gallbladder Cancer, Lynch Syndrome, Colorectal Cancer, Gallbladder Adenocarcinoma, and Bone Marrow Aspiration. Dr. Singh is board certified in American Board Of Internal Medicine, Hematology.

Frequently Asked Questions about Dr. Shylendra B. Sreenivasappa

How do I make an appointment with Dr. Shylendra B. Sreenivasappa?

You can book an appointment with Dr. Shylendra B. Sreenivasappa by calling their office at 815-227-2273. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Shylendra B. Sreenivasappa a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Shylendra B. Sreenivasappa is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Shylendra B. Sreenivasappa specialize in?

While Dr. Shylendra B. Sreenivasappa is a Hematology, they have specific expertise in Colorectal Cancer, Iron Deficiency Anemia, and Lynch Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Shylendra B. Sreenivasappa accept my insurance?

Dr. Shylendra B. Sreenivasappa accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 815-227-2273 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sreenivasappa's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 28 Advanced Conditions
    View All 139 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile